Transmucosal Patch Electrospun Fibers Cannabinoid Opioid Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pain relief medications, such as morphine and antidepressants, have significant side effects and variability in efficacy due to gastrointestinal absorption, while cannabinoid-based treatments face challenges with bioavailability and stability in the oral cavity.
Innovation Solution
A transmucosal patch comprising electrospun fibers with biocompatible polymers and a combination of cannabinoids and opioids, designed for immediate or controlled release, adheres to the oral mucosa for direct absorption, optimizing bioavailability and minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional pain relief medications (morphine, opioids) are used, then effective pain relief is achieved, but side effects and risk of overdosing increase
Solution Approach 1:
The patent combines cannabinoids and opioids in a single transmucosal patch formulation. This composite approach allows the cannabinoids to modulate the effects of opioids, potentially reducing required opioid doses and associated side effects while maintaining pain relief efficacy. The electrospun fiber matrix integrates both active ingredients for协同 action.
Solution Approach 2:
Cannabinoids act as intermediary substances that modulate opioid reception and effect. The patch delivers cannabinoids alongside opioids, where cannabinoids serve as mediators to enhance pain relief while reducing the harmful effects of opioids, such as respiratory depression and addiction potential.
2Ease of operation
If cannabinoids are administered orally, then treatment is simple, but bioavailability is poor due to first-pass metabolism
Solution Approach 1:
The patent extracts cannabinoids from oral administration pathway by using transmucosal delivery. The electrospun patch bypasses gastrointestinal absorption and hepatic first-pass metabolism by delivering cannabinoids directly through the oral mucosa into systemic circulation, thereby extracting the harmful metabolic pathway while maintaining administration simplicity.
3Quantity of substance
If electrospun fibers are used for transmucosal delivery, then bioavailability is improved, but manufacturing complexity increases
Solution Approach 1:
The patent optimizes electrospinning parameters (voltage, flow rate, needle-to-collector distance, polymer concentration) to control fiber morphology, size, and drug loading. By systematically adjusting these parameters, the manufacturing process achieves consistent high-quality patches with controlled drug release profiles, balancing manufacturing complexity with improved bioavailability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The patch provides fast, uniform, and high bioavailability of cannabinoids and opioids, reducing side effects and variability, offering effective pain relief and anxiety treatment without gastrointestinal first-pass metabolism.
Implementation Method 1
A transmucosal patch comprising electrospun fibers with biocompatible polymers and a combination of cannabinoids and opioids, designed for immediate or controlled release, adheres to the oral mucosa for direct absorption
Implementation Method 2
The patch comprises electrospun biocompatible polymer fibers
Data Source
AI summary
The invention relates to a transmucosal patch comprising electrospun fibers comprising a biocompatible polymer and a therapeutically effective amount of a pharmaceutical active ingredient, wherein the active pharmaceutical ingredient comprises a cannabinoid or an opioid or a cannabinoid and an opioid, and its use as a medicament.